LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) shares rose 8% on Friday . The stock traded as high as $26.80 and last traded at $27.52. Approximately 27,886 shares traded hands during trading, a decline of 84% from the average daily volume of 171,762 shares. The stock had previously closed at $25.48.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $35.40.
Read Our Latest Research Report on LENZ Therapeutics
LENZ Therapeutics Stock Performance
The business has a 50 day moving average of $29.28 and a two-hundred day moving average of $26.84.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.09. During the same period in the prior year, the business earned ($1.33) EPS. Analysts anticipate that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.
Institutional Trading of LENZ Therapeutics
Several institutional investors have recently made changes to their positions in LENZ. Harbor Capital Advisors Inc. bought a new stake in LENZ Therapeutics in the 4th quarter worth about $1,270,000. Parkman Healthcare Partners LLC purchased a new stake in shares of LENZ Therapeutics during the third quarter valued at approximately $3,308,000. The Manufacturers Life Insurance Company purchased a new stake in shares of LENZ Therapeutics during the third quarter valued at approximately $743,000. Barclays PLC lifted its holdings in LENZ Therapeutics by 273.1% during the third quarter. Barclays PLC now owns 16,463 shares of the company's stock worth $391,000 after acquiring an additional 12,051 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in LENZ Therapeutics by 197.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company's stock valued at $2,929,000 after purchasing an additional 81,901 shares during the period. Institutional investors own 54.32% of the company's stock.
LENZ Therapeutics Company Profile
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Read More
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
